6 completed, 3 terminated, 2 unknown. 11 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 6, Terminated 3, Unknown 2 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Chronic Hepatitis C Infection: new trials by email Literature Review of Chronic Hepatitis C Infection trials Research Report on Chronic Hepatitis C Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutic Hepatitis C Virus Vaccine HCVax - Chronic Hepatitis C Infection | Phase 1 | Unknown | GeneCure Biotechnologies | 30 | 2021-04-20 | 2021-09-29 |
| Clinical Investigation of Erlotinib as an HCV Entry Inhibitor 1- Erlotinib, placebo - Chronic Hepatitis C Infection, HCV Genotype 1b | Phase 1 / Phase 2 | Unknown | University Hospital, Strasbourg, France | 12 | 2013-05-01 | 2014-06-17 |
| To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006) Samatasvir, Omeprazole, Ritonavir - Chronic Hepatitis C Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2013-02-01 | 2016-01-22 |
| Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) IDX719, Simeprevir - Chronic Hepatitis C Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 42 | 2013-01-01 | 2016-01-26 |
| Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants ACH-0143102, Ribavirin - Chronic Hepatitis C Infection | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 8 | 2012-09-01 | 2023-08-29 |
| Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382 Placebo, JNJ-47910382 - Chronic Hepatitis C Infection | Phase 1 | Terminated | Janssen R&D Ireland | 11 | 2012-08-01 | 2014-05-12 |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients JNJ-47910382 30 mg, JNJ-47910382 90 mg, JNJ-47910382 200 mg - Chronic Hepatitis C Infection | Phase 1 | Terminated | Janssen R&D Ireland | 8 | 2012-05-25 | 2019-03-27 |
| Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I) Valacyclovir, Placebo - Chronic Hepatitis C Infection | Phase 1 | Completed | VA Office of Research and Development | 31 | 2011-11-01 | 2016-11-22 |
| A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin - Chronic Hepatitis C Infection, Genotype 1 | Phase 1 / Phase 2 | Completed | HanAll BioPharma Co., Ltd. | 30 | 2011-06-23 | 2025-04-22 |
| Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029) Vaniprevir - Chronic Hepatitis C Infection | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 3 | 2010-01-13 | 2018-10-18 |
| Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults VBY 376 - Chronic Hepatitis C Infection | Phase 1 | Completed | Virobay Inc. | 48 | 2007-11-01 | 2013-12-31 |
Hepatitis C (6)
Blood-Borne Infections (6) · Communicable Diseases (6) · Digestive System Diseases (6) · Flaviviridae Infections (6) · Hepatitis (6) · Hepatitis, Viral, Human (6) · Infections (6) · Liver Diseases (6) · RNA Virus Infections (6) · Virus Diseases (6)
Ribavirin (2) · samatasvir (2) · Omeprazole (1) · Ritonavir (1) · Simeprevir (1) · Valacyclovir (1) · peginterferon alfa-2a (1) · vaniprevir (1)
Merck Sharp & Dohme LLC (3) · Janssen R&D Ireland (2) · Alexion Pharmaceuticals, Inc. (1) · GeneCure Biotechnologies (1) · HanAll BioPharma Co., Ltd. (1) · University Hospital, Strasbourg, France (1) · VA Office of Research and Development (1) · Virobay Inc. (1)
United States (4) · France (1) · Germany (1) · Taiwan (1)
Dr Catherine Mutter, MD (1) · Dr Samira Fafi-Kremer, Pharma D, PhD (1) · Mary J Burton, MD (1) · Stephen D Flach, MD (1)
2009 (1)